Back to News
Market Impact: 0.25
United Therapeutics Announces FDA Acceptance Of SNDA For Nebulized Tyvaso In IPF
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct LaunchesCompany Fundamentals
United Therapeutics (UTHR) said the U.S. FDA accepted its supplemental New Drug Application for nebulized Tyvaso Inhalation Solution to treat idiopathic pulmonary fibrosis. The FDA acceptance is a positive regulatory milestone that can support the program’s path forward, though it does not yet imply approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
UTHR0.45
More News
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Palantir patient data tech rejected by many NHS trusts in England
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- Stock fixing scandal could see Turkish companies frozen out of global indexes
- Tesla is taking $250,000 deposits for a Roadster with SpaceX thrusters. The FAA says it isn’t an aircraft
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'